Search results for "From ACP Journal Club"
In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y
A subanalysis of a trial of empagliflozin for patients with cardiovascular disease (CVD) found lower rates of nephropathy in those randomized to empagliflozin rather than placebo.
https://diabetes.acponline.org/archives/2016/11/11/7.htm
11 Nov 2016
Review: Metformin is linked to reduced mortality in type 2 diabetes with comorbid CKD and CHF
The included studies focused on metformin use in patients with chronic kidney disease (CKD), congestive heart failure (CHF), chronic liver disease (CLD), or older age.
https://diabetes.acponline.org/archives/2017/05/12/7.htm
12 May 2017
In screen-detected type 2 diabetes, intensive therapy did not differ from usual care for CV events at 10 years
Despite the lack of observed benefit in this analysis, primary care physicians should continue to operate under the reasonable assumption that addressing cardiovascular (CV) risk factors improves longevity, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/05/08/6.htm
8 May 2020
Self-monitoring of blood glucose did not improve HbA1c or QOL at 1 year in non-insulin-treated type 2 diabetes
The randomized controlled trial adds to the evidence about routine use of self-monitoring of blood glucose for all patients with type 2 diabetes, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2017/11/10/7.htm
10 Nov 2017
In acute ischemic stroke with hyperglycemia, intensive vs standard glucose control did not improve 90-day outcomes
Several factors, including high rates of reperfusion therapy and early hospital discharge, may explain why this trial found no benefit from intensive glucose control after stroke, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/01/10/7.htm
10 Jan 2020
Risk scores overestimated risk for CVD in newly diagnosed type 2 diabetes
Available risk scores are in need of recalibration but still serve as useful decision-making tools, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/12/14/8.htm
14 Dec 2018
Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo
A review published prior to the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial found that aspirin only reduced cardiovascular events in diabetes patients with pre-existing cardiovascular disease.
https://diabetes.acponline.org/archives/2016/12/09/5.htm
9 Dec 2016
Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease
Sodium–glucose cotransporter 2 inhibitors appear to be a promising treatment option for patients with diabetes and chronic kidney disease, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/09/13/6.htm
13 Sep 2019
Studies analyze amputation rates with sodium–glucose cotransporter-2 inhibitors
An ACP Journal Club commentary looked at studies on the effects of canagliflozin in patients with cardiovascular disease and dapagliflozin in patients with peripheral artery disease, concluding that amputation risks are small enough that they needn't play a major role in prescribing decisions.
https://diabetes.acponline.org/archives/2021/02/12/7.htm
12 Feb 2021
SGLT2 inhibitors reduce all-cause mortality
A recent meta-analysis found lowered mortality risk with sodium-glucose cotransporter-2 (SGLT2) inhibitors, and an ACP Journal Club commentary added that other trials have shown beneficial effects of the drug class on kidney function in patients with type 2 diabetes.
https://diabetes.acponline.org/archives/2021/05/14/6.htm
14 May 2021